Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates
Related Experiment Video
Updated: Jul 12, 2026
Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach
Published on: December 1, 2011
Andrew J Low1, Winnie Dong, Dennison Chan
1B.C. Centre for Excellence in HIV/AIDS St. Paul's Hospital, Vancouver, British Columbia, Canada.
Objective:
Integrating CCR5 antagonists into clinical practice would benefit from accurate assays of co-receptor usage (CCR5 versus CXCR4) with fast turnaround and low cost.
Design:
Published HIV V3-loop based predictors of co-receptor usage were compared with actual phenotypic tropism results in a large cohort of antiretroviral naive individuals to determine accuracy on clinical samples and identify areas for improvement.
Methods:
Aligned HIV envelope V3 loop sequences (n = 977), derived by bulk sequencing were analyzed by six methods: the 11/25 rule; a neural network (NN), two support vector machines, and two subtype-B position specific scoring matrices (PSSM). Co-receptor phenotype results (Trofile Co-receptor Phenotype Assay; Monogram Biosciences) were stratified by CXCR4 relative light unit (RLU) readout and CD4 cell count.
Results:
Co-receptor phenotype was available for 920 clinical samples with V3 genotypes having fewer than seven amino acid mixtures (n = 769 R5; n = 151 X4-capable). Sensitivity and specificity for predicting X4 capacity were evaluated for the 11/25 rule (30% sensitivity/93% specificity), NN (44%/88%), PSSM(sinsi) (34%/96%), PSSM(x4r5) (24%/97%), SVMgenomiac (22%/90%) and SVMgeno2pheno (50%/89%). Quantitative increases in sensitivity could be obtained by optimizing the cut-off for methods with continuous output (PSSM methods), and/or integrating clinical data (CD4%). Sensitivity was directly proportional to strength of X4 signal in the phenotype assay (P < 0.05).
Conclusions:
Current default implementations of co-receptor prediction algorithms are inadequate for predicting HIV X4 co-receptor usage in clinical samples, particularly those X4 phenotypes with low CXCR4 RLU signals. Significant improvements can be made to genotypic predictors, including training on clinical samples, using additional data to improve predictions and optimizing cutoffs and increasing genotype sensitivity.
Insights
Accurate HIV co-receptor usage prediction is crucial for CCR5 antagonist therapy. Current genotypic algorithms show low sensitivity for X4 tropism in clinical samples, necessitating algorithm improvement for better patient outcomes.
Area of Science:
- Virology
- Infectious Diseases
- Computational Biology
Background:
- Accurate determination of HIV co-receptor usage (CCR5 vs. CXCR4) is essential for effective treatment with CCR5 antagonists.
- Existing genotypic prediction methods for HIV tropism require validation and improvement for clinical utility.
Purpose of the Study:
- To evaluate the accuracy of published HIV V3-loop based predictors of co-receptor usage against phenotypic tropism results.
- To identify areas for improvement in genotypic tropism prediction algorithms using clinical samples.
Main Methods:
- Six different V3-loop sequence analysis methods were compared: 11/25 rule, neural network, two support vector machines, and two PSSMs.
- Analysis was performed on 977 HIV V3-loop sequences from antiretroviral-naive individuals, with co-receptor phenotype data available for 920 samples.
- Phenotypic results were stratified by CXCR4 relative light unit (RLU) readout and CD4 cell count.
Main Results:
- The evaluated genotypic predictors demonstrated variable sensitivity and specificity for predicting X4 co-receptor usage.
- The best performing method, SVMgeno2pheno, achieved 50% sensitivity and 89% specificity.
- Sensitivity was directly proportional to the strength of the X4 signal in the phenotype assay, and improvements could be achieved by optimizing cut-offs and integrating clinical data (CD4 count).
Conclusions:
- Current default implementations of HIV co-receptor prediction algorithms are inadequate for clinical settings, especially for X4 phenotypes with low CXCR4 RLU signals.
- Significant improvements in genotypic predictors are possible through training on clinical samples, incorporating additional data, optimizing cutoffs, and enhancing genotype sensitivity.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:29Pharmacogenomics: Identification of New Drug Targets